FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006647054> ?p ?o ?g. }

• W2006647054 endingPage "S118" @default.
• W2006647054 startingPage "S118" @default.
• W2006647054 abstract "Little is known about the efficiency of chemotherapy in advanced biliary tract carcinoma. Accordingly, we conducted a phase II study of combined 5FU CI and P in this disease. 28 patients (pts) (13 M/15 F) were included. Median age: 57 years. ECOG performance status: grade (g) 0;1: 79%, g 2: 18%, g 3: 3%. More than 10% weight loss: 36% Primary tumor: gallbladder: 11, Vater ampulla: 5, cholangiocarcinoma: 5, bile ducts: 7. 25 patients had metastases, 2 had local recurrences of their tumor and 1 a nodulary intrahepatic non resectable form. Sites of the metastases: liver: 12 pts, abdominal lymph nodes: 6 pts, lung: 6 pts, peritoneum: 6 pts, mediastinal lymph nodes: 1 pt. Treatment schedule: 5FU CI: 1 g/m2 × 5 days, P: 100 mg/m2 day 2 repeated every 4 weeks. Results Median number of cycles: 4. 25 pts are evaluable for the tumor response (1 too early, 2 non evaluable), no complete response, partial response (PR): 8, objective response rate = 29% (CI: 12–46%). Minor response: 2, stabilisation: 10, progressive disease: 6. Toxicity was tolerable: g 3 vomiting: 21% of the pts, g 3 mucositis: 4%. Some pts experienced haematological toxicity: g 3 granulocytopenia: 18%, g 4: 4%; no g 3–4 thrombocytopenia. Other toxicities: g 1–2 renal: 3 pts; g 1 neuropathy: 1 pt. No toxic death. Median survival was 10 months and 1-year actuarial survival 33%. We conclude that this regimen is tolerable and active in patients with advanced biliary tract cancer. Little is known about the efficiency of chemotherapy in advanced biliary tract carcinoma. Accordingly, we conducted a phase II study of combined 5FU CI and P in this disease. 28 patients (pts) (13 M/15 F) were included. Median age: 57 years. ECOG performance status: grade (g) 0;1: 79%, g 2: 18%, g 3: 3%. More than 10% weight loss: 36% Primary tumor: gallbladder: 11, Vater ampulla: 5, cholangiocarcinoma: 5, bile ducts: 7. 25 patients had metastases, 2 had local recurrences of their tumor and 1 a nodulary intrahepatic non resectable form. Sites of the metastases: liver: 12 pts, abdominal lymph nodes: 6 pts, lung: 6 pts, peritoneum: 6 pts, mediastinal lymph nodes: 1 pt. Treatment schedule: 5FU CI: 1 g/m2 × 5 days, P: 100 mg/m2 day 2 repeated every 4 weeks. Median number of cycles: 4. 25 pts are evaluable for the tumor response (1 too early, 2 non evaluable), no complete response, partial response (PR): 8, objective response rate = 29% (CI: 12–46%). Minor response: 2, stabilisation: 10, progressive disease: 6. Toxicity was tolerable: g 3 vomiting: 21% of the pts, g 3 mucositis: 4%. Some pts experienced haematological toxicity: g 3 granulocytopenia: 18%, g 4: 4%; no g 3–4 thrombocytopenia. Other toxicities: g 1–2 renal: 3 pts; g 1 neuropathy: 1 pt. No toxic death. Median survival was 10 months and 1-year actuarial survival 33%. We conclude that this regimen is tolerable and active in patients with advanced biliary tract cancer." @default.
• W2006647054 created "2016-06-24" @default.
• W2006647054 creator A5011190816 @default.
• W2006647054 creator A5033525798 @default.
• W2006647054 creator A5039819726 @default.
• W2006647054 creator A5047771337 @default.
• W2006647054 creator A5052894192 @default.
• W2006647054 creator A5056786063 @default.
• W2006647054 creator A5082689339 @default.
• W2006647054 date "1995-11-01" @default.
• W2006647054 modified "2023-09-27" @default.
• W2006647054 title "554 Demonstrated efficiency of 5fluorouracil (5FU) continuous infusion (CI) and cisplatin (P) in patients with advanced biliary tract carcinoma" @default.
• W2006647054 doi "https://doi.org/10.1016/0959-8049(95)95808-j" @default.
• W2006647054 hasPublicationYear "1995" @default.
• W2006647054 type Work @default.
• W2006647054 sameAs 2006647054 @default.
• W2006647054 citedByCount "0" @default.
• W2006647054 crossrefType "journal-article" @default.
• W2006647054 hasAuthorship W2006647054A5011190816 @default.
• W2006647054 hasAuthorship W2006647054A5033525798 @default.
• W2006647054 hasAuthorship W2006647054A5039819726 @default.
• W2006647054 hasAuthorship W2006647054A5047771337 @default.
• W2006647054 hasAuthorship W2006647054A5052894192 @default.
• W2006647054 hasAuthorship W2006647054A5056786063 @default.
• W2006647054 hasAuthorship W2006647054A5082689339 @default.
• W2006647054 hasConcept C126322002 @default.
• W2006647054 hasConcept C141071460 @default.
• W2006647054 hasConcept C2775982439 @default.
• W2006647054 hasConcept C2776694085 @default.
• W2006647054 hasConcept C2776907518 @default.
• W2006647054 hasConcept C2777148285 @default.
• W2006647054 hasConcept C2778496288 @default.
• W2006647054 hasConcept C2778822529 @default.
• W2006647054 hasConcept C2781413609 @default.
• W2006647054 hasConcept C29730261 @default.
• W2006647054 hasConcept C71924100 @default.
• W2006647054 hasConcept C90924648 @default.
• W2006647054 hasConceptScore W2006647054C126322002 @default.
• W2006647054 hasConceptScore W2006647054C141071460 @default.
• W2006647054 hasConceptScore W2006647054C2775982439 @default.
• W2006647054 hasConceptScore W2006647054C2776694085 @default.
• W2006647054 hasConceptScore W2006647054C2776907518 @default.
• W2006647054 hasConceptScore W2006647054C2777148285 @default.
• W2006647054 hasConceptScore W2006647054C2778496288 @default.
• W2006647054 hasConceptScore W2006647054C2778822529 @default.
• W2006647054 hasConceptScore W2006647054C2781413609 @default.
• W2006647054 hasConceptScore W2006647054C29730261 @default.
• W2006647054 hasConceptScore W2006647054C71924100 @default.
• W2006647054 hasConceptScore W2006647054C90924648 @default.
• W2006647054 hasLocation W20066470541 @default.
• W2006647054 hasOpenAccess W2006647054 @default.
• W2006647054 hasPrimaryLocation W20066470541 @default.
• W2006647054 hasRelatedWork W1966165324 @default.
• W2006647054 hasRelatedWork W1982603734 @default.
• W2006647054 hasRelatedWork W2006647054 @default.
• W2006647054 hasRelatedWork W2134112440 @default.
• W2006647054 hasRelatedWork W2316688895 @default.
• W2006647054 hasRelatedWork W2365983310 @default.
• W2006647054 hasRelatedWork W2410470690 @default.
• W2006647054 hasRelatedWork W2462006681 @default.
• W2006647054 hasRelatedWork W3149467385 @default.
• W2006647054 hasRelatedWork W4254089574 @default.
• W2006647054 hasVolume "31" @default.
• W2006647054 isParatext "false" @default.
• W2006647054 isRetracted "false" @default.
• W2006647054 magId "2006647054" @default.
• W2006647054 workType "article" @default.